科研之友
微信
新浪微博
Facebook
分享链接
摘要
Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer.
- 出版日期2014-9
